296 related articles for article (PubMed ID: 35568716)
1. Targeting the apoptosis pathway to treat tumours of the paediatric nervous system.
Fitzgerald MC; O'Halloran PJ; Connolly NMC; Murphy BM
Cell Death Dis; 2022 May; 13(5):460. PubMed ID: 35568716
[TBL] [Abstract][Full Text] [Related]
2. Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway.
Gupta SC; Francis SK; Nair MS; Mo YY; Aggarwal BB
J Biol Chem; 2013 Nov; 288(45):32343-32356. PubMed ID: 24078627
[TBL] [Abstract][Full Text] [Related]
3. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
4. Developing TRAIL/TRAIL death receptor-based cancer therapies.
Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
[TBL] [Abstract][Full Text] [Related]
5. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
[TBL] [Abstract][Full Text] [Related]
6. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
8. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
9. Spatial dynamics of TRAIL death receptors in cancer cells.
Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
[TBL] [Abstract][Full Text] [Related]
10. Targeting TRAIL in the treatment of cancer: new developments.
Lim B; Allen JE; Prabhu VV; Talekar MK; Finnberg NK; El-Deiry WS
Expert Opin Ther Targets; 2015; 19(9):1171-85. PubMed ID: 26004811
[TBL] [Abstract][Full Text] [Related]
11. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
12. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
13. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
Johnstone RW; Frew AJ; Smyth MJ
Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
[TBL] [Abstract][Full Text] [Related]
14. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
17. The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).
Mellier G; Pervaiz S
Free Radic Res; 2012 Aug; 46(8):996-1003. PubMed ID: 22559302
[TBL] [Abstract][Full Text] [Related]
18. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.
Mazurek N; Byrd JC; Sun Y; Hafley M; Ramirez K; Burks J; Bresalier RS
Cell Death Differ; 2012 Mar; 19(3):523-33. PubMed ID: 21941373
[TBL] [Abstract][Full Text] [Related]
19. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
20. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
